Updated with additional information from 1:35 pm EST

SAN FRANCISCO ( TheStreet) -- MannKind (MNKD) CEO Al Mann is retiring and the company's inhaled insulin device Afrezza still has no publicly disclosed commercial launch date. 

Elias Zerhouni, Sanofi's (SNY) president of research and development, just finished speaking at the J.P. Morgan Healthcare Conference. He focused much of his talk on 18 drug launches that are expected during the next six years, including three new diabetes medicines.

Number of slides in Zerhouni's presentation devoted to the Toujeo: Five.
Number of slides devoted to Lixilan: 2
Number of slides devoted to Afrezza: 1. Here it is:

Zerhouni said nothing in his presentation about when Afrezza would launch commercially, other than to say this year. Nothing was said about the product's cost. During the subsequent breakout session, Sanofi reportedly told investors Afrezza would launch in the current quarter, which is in line with previous statements.

Perhaps even more interesting, Zerhouni's brief remarks about Afrezza focused exclusively on the inhalable device's relative ease of use compared to injectable insulin. MannKind and its supporters believe Afrezza represents a superior form of insulin for diabetics. If Sanofi believes that, it wasn't mentioned on Monday, but Zerhouni spent quite a bit of time describing Toujeo as a "new gold standard" for basal insulin. 

Earlier Monday, MannKind announced the retirement of the company's founder and CEO, Al Mann. He will be replaced as CEO by current president, Hakan Edstrom. 

"In Hakan We Trust" doesn't have the same ring. 

MannKind shares are down 5% to $5.47 in recent trading.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.